Allarity Therapeutics, Inc. (ALLR)

$0.248

-0.00 (-0.80%)
Rating:
Recommendation:
-
Symbol ALLR
Price $0.248
Beta -0.003
Volume Avg. 2.12M
Market Cap 3.578M
Shares () -
52 Week Range 0.2-9.219
1y Target Est -
DCF Unlevered ALLR DCF ->
DCF Levered ALLR LDCF ->
ROE -173.30% Strong Sell
ROA -106.53% Strong Sell
Operating Margin -
Debt / Equity 417.67% Strong Buy
P/E -
P/B 0.70 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Healthcare
Biotechnology
NASDAQ Global Market

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.